Kush M. Parmar
Independent Chairman of the BoardDr. Kush M. Parmar, M.D. Ph.D., is Director of Precede Biosciences, Inc. Dr. Parmar was Treasurer, Secretary & Director of Precede Biosciences, Inc. Dr. Parmar has been Chairman of the Board at Entrada Therapeutics, Inc. since December 2020 and has been its Director since October 2016. He serves as Director of GlycoEra AG since July 12, 2022. He has been Director at ProLynx LLC since September 2025. He served as a Director of Rallybio, LLC until 2024. Dr. Parmar was Independent Non-Executive Director of Syngene International Limited until July 29, 2026. He had been Additional Independent Non-Executive Director of Syngene International Limited since June 22, 2021. Dr. Parmar was Independent Director at Rallybio Corporation since April 2018 until October 31, 2024. He served as Chief Executive Officer and President of Ensoma, Inc. until October 2021. He serves as Director of Ensoma, Inc. and served as its Secretary. He has been the Co-Chief Executive Officer and Director at 5:01 Acquisition Corp. since August 2020. Dr. Parmar is a Managing Partner and Member at 5AM Venture Management LLC since January 2016. Dr. Parmar is also Acting Vice President of Strategy and Corporate Development at Novira Therapeutics, Inc. He served as a Partner at 5AM Venture Management LLC from January 2014 to December 2016 and a Principal from January 2012 to December 2014 at 5AM Ventures. He served as a Principal and Senior Associate of 5AM Venture Management LLC. He joined 5AM Ventures in June 2010. He is Co-Owner of 5:01 Acquisition LLC. He served as the Chairman of Vor Biopharma, Inc. since January 2021 until June 2021 and was its Independent Director from February 2019 to April 12, 2023. He was Interim President and Chief Executive Officer at Vor Biopharma Inc. since February 2019 until August 2019. Dr. Parmar served as the President at Homology Medicines, Inc. He has experience in the life sciences industry and has experience as a venture capitalist and senior executive. He founded the Cruz Blanca Initiative. He consulted for a Boston area oncology startup. Dr. Parmar served as Director at Syngene International Ltd. since July 2020. He previously served as a board member or observer for Pulmatrix, Inc. Dr. Parmar serves as a Director of Achaogen, Atterocor, Cleave Biosciences, Novira Therapeutics. Dr. Parmar had been a Director of Arvinas, Inc. since 2013 until November 2019. Dr. Parmar has been a Director of CycloPorters since 2016. He was a Director of Homolgy since 2015 until September 2022. He served as the Chairman of the Board at Homology Medicines since March 2018 until September 2022 and had been its Independent Director since December 2015 until September 2022. He had been a Director of Akouos, Inc. since October 2017 until December 1, 2022. He served as an Independent Director of Audentes Therapeutics, Inc. since July 18, 2013 until November 5, 2018. Dr. Parmar was a Director of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since March 2014 until July 20, 2018. Dr. Parmar serves on the Scientific Advisory Council of Princeton University's Department of Molecular Biology and member of the scientific advisory board of Grace Science Foundation. He served as a Board Observer of Envoy Therapeutics and Achaogen. He attended courses at Harvard Business School in Private Equity and Finance. He is also a Fellow of the Kauffman Fellows Society. Dr. Parmar's doctoral work at Harvard focused on cardiovascular biology and was published in The Journal of Clinical Investigation and the Journal of Biological Chemistry. Dr. Parmar is a Managing Partner at 5AM Ventures. He is a founding member of the COVID R&D Alliance along with several heads of R&D of global pharmaceutical companies. Dr. Parmar worked on developmental genetics with Nobel Prize winner Eric F. Wieschaus. He completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. Dr. Parmar was a National Institute of Health Physician Scientist Fellow at Harvard Medical School. Dr. Parmar serves as on the advisory boards of Harvard Medical School and Penn Medicine. Dr. Parmar holds a Ph.D. in Experimental Pathology from Harvard University from 2004 to 2008. He holds an M.D. from Harvard Medical School from 2002 to 2010, where he was an NIH-sponsored M.D. and Ph.D. Physician Scientist Trainee in the joint Harvard-MIT Health Sciences and Technology Program. Dr. Parmar holds an A.B. in Molecular Biology and Medieval Studies from Princeton University from 1998 to 2002.
Positions
- Company NameEntrada Therapeutics, Inc.Stock CodeTRDAPositionIndependent Chairman of the BoardColleagues
- DDDipal DoshiCEO & Director
- NJNathan J. DowdenPresident & COO
- NSNatarajan SethuramanPresident of Research & Development
- KJKory James WentworthCFO & Treasurer
- JCJared CohenGeneral Counsel
- MTMary T. ThistleIndustry Leader & Independent Director
- PSPeter S. KimDirector
- BGBernhardt G. ZeiherIndependent Director
